Paul Wei and another pyramid rebalancing trader reached a consensus on the take-profit range, with BTC's short-term high expected to reach $78,000.
BlockBeats News, March 16, according to reports, two traders on Hyperliquid using pyramid position management strategies—"Paul Wei" (0xdae) and "100% Win Rate Low Drawdown" (0x721)—have reached consensus today on the BTC long position take-profit range.
Both have placed orders targeting BTC's short-term high near $78,000. "Paul Wei" set take-profit orders in the $75,000 to $78,100 range over the past hour, while the other trader had already placed orders in this range two days ago.
Additionally, regarding the next round of long position additions, the "100% Win Rate Low Drawdown" trader placed 50 buy orders in pyramid mode over the past hour, planning to accumulate long positions in batches within the $68,000 to $70,500 range if BTC falls below $70,500. "Paul Wei" is more conservative, planning to add positions only when BTC drops near $66,500.
For leverage selection, "Paul Wei" uses 2 to 3 times leverage to adjust positions steadily within a wide range, while "100% Win Rate Low Drawdown" uses 20 times leverage in a narrow range to pursue higher returns, and his principal has tripled.
Both traders adopt a range pyramid position management strategy: progressively arranging long and short positions and take-profit orders within a defined volatility range, profiting by repeatedly capturing price fluctuations, rather than using Martingale strategies or betting on unilateral trends.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Morgan Stanley senior bond investor turns bullish on US Treasuries for the first time in ten years
US Stock Movement | SuperX AI Technology (SUPX.US) once fell more than 2.5%, hitting an intraday low of $6.46
SuperX AI Technology's stock price declined, falling more than 2.5% at one point.
BUZZ-Pacira BioSciences participated in a Viatris acquisition deal worth 1.65 billions dollars
Latest Update October 8 – Pacira BioSciences (PCRX.O) shares surged by 44%, hitting a more than three-year high at $36.30. If the rally holds, PCRX is poised for its largest single-day gain on record. Pharmaceutical company Viatris (VTRS.O) will acquire Pacira BioSciences in a $1.65 billion cash deal, offering $36.50 per share. The offer represents a premium of approximately 44.8% over Pacira’s recent closing price of $25.20. The transaction will add Pacira’s non-opioid pain medications Exparel and Zilretta to Viatris' product portfolio. Viatris shares fell 2.6% to $17.04. JPMorgan stated: “We believe this acquisition will not significantly alter VTRS' overall financial profile in the short or long term, and expect Exparel’s sales to gradually decline post-2030 due to generic market entry.” Both parties expect to complete the transaction by the end of 2026. Including intraday fluctuations, PCRX shares have risen 40.2% year-to-date, while VTRS has gained 36.8%. (For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. As automated translation may contain errors or lack the necessary context, Reuters does not guarantee the accuracy of automated translated texts and provides them for readers’ convenience only. Reuters assumes no liability for any damage or losses resulting from the use of automated translation.)
Crypto prices
More
